September 30, 2010

Merging of marketing and medical science: female sexual dysfunction

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Researching his latest book, Ray Moynihan uncovered how drug companies helped construct the scientific building blocks of a new condition. Here he asks whether we need a fresh approach to defining disease

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Ruby Moynihan (Thu,) studied this question.

synapsesocial.com/papers/6a20f5643b29bd64a5eb1d8d https://doi.org/https://doi.org/10.1136/bmj.c5050

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function2000 · 6,504 citations
2Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors2004 · 1,410 citations
3Conflict of Interest in Medical Research, Education, and Practice2009 · 810 citations
4Major changes are proposed for definitions of female sexual dysfunction2010 · 3 citations
5Drug for low sexual desire carries significant harms, FDA advisers find2010 · 3 citations

Preguntar a la IA

Me gusta

Guardar